Lux Biosciences Receives Complete Response Letter from FDA for Luveniq(TM)

Published: Aug 04, 2010

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration’s Center of Drug Evaluation and Research has issued a Complete Response letter regarding the New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis.

Back to news